Skip to content

Raising Insulin Sensitivity in Post Menopause

Tissue Selective Estrogen Complex to Prevent Metabolic Dysfunction in Women

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02274571
Acronym
RISE
Enrollment
8
Registered
2014-10-24
Start date
2015-09-30
Completion date
2017-04-11
Last updated
2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause

Brief summary

The purpose of this study is to find out if a novel drug approved by the Food and Drug Administration \[Duavee™, Pfizer, Inc\] for treatment of postmenopausal symptoms (vaginal dryness and hot flashes) and prevention of osteoporosis also improves insulin sensitivity by decreasing body fat especially in your liver. DUAVEE™ (Conjugated Estrogens/Bazedoxifene) is a new prescription medicine that contains a mixture of estrogen (the main female hormone made by the ovaries) and bazedoxifene, which is FDA approved. For over 60 years, estrogens have been used as hormonal treatments to help manage hot flashes and help prevent postmenopausal bone loss. But in the treatment of postmenopausal women, the use of estrogens alone can increase the risk of developing cancer of the uterus. So estrogens have been traditionally paired with a progestin to decrease the risk of hyperplasia (the thickening of the lining of the uterus), which can be a precursor to cancer. DUAVEE™ uses bazedoxifene, a selective estrogen receptor modulator (SERM), in place of a progestin to help protect the uterus against thickening of the uterus that may result from estrogens alone. In this study, you will get either DUAVEE™ or the placebo (a dummy pill that may look like medicine but contains no active medication) first and then switch to the other pill.

Detailed description

This study involves a screening process to see if you are eligible to participate followed by two 8-week treatment periods separated by an 8-week washout period. The two 8-week treatments will be with: 1. 8 weeks of treatment with TSEC (Duavee™, combination of CE and BZA) 2. 8 weeks of treatment with a dummy pill (Placebo) The order of these 2 8-week treatment periods will be decided by chance (coin flip). STUDY VISITS (11 VISITS in total) If you participate in this study, after referral from the Baton Rouge General Obstetrics and Gynecology Physicians, you will complete 1 screening visit at Pennington Biomedical Research Center to determine your eligibility. If you are eligible and enrolled in the study, you will complete an additional 10 visits (8 brief visits and 2 overnight inpatient stays). Please note all times provided for procedures and the total times for each clinic visit are approximations and may vary depending on circumstances. SCREENING VISIT (1 visit, approximately 1.5 hours, fasting): Please do not drink any food or water for 10 hours before this appointment. Participants are asked to report to the Pennington clinic fasting. After a detailed explanation of the whole study by a coordinator, if you agree to the procedures by signing a consent form, you will have: 1. Your height and body weight measured. 2. You will then have an ECG (electrocardiogram) to measure your heart rate and rhythm. 3. Your blood pressure will be measured. 4. A blood sample (\<1 teaspoon) and urine will be collected to assess your general health. 5. You will have a medical history and physical examination. If fully eligible according to the data collected during the screening visit, you will be called to set up a second visit to provide you with the medication or the dummy pill. VISIT 2 (30 minutes): You will come to the Pennington to pick up your drug supply (real medication or dummy pill) and meet with a nurse or a study coordinator to give you instructions on when and how to take your pill once a day. VISITS 3-5 (30 minutes each): At week 1, 3, and 5 of your 8-week treatment period, you will come to our outpatient clinic to measure your weight, blood pressure and pulse, collect some feedback on your health and check your medication compliance as well as distribute new medications. VISIT 6 (24 hours at our inpatient unit): You will be admitted to our inpatient unit at 4pm (not fasted) for measures of: 1. Total body fat by DXA 2. Abdominal visceral fat by Magnetic Resonance Imaging (MRI) 3. Fat in your liver and muscle by Magnetic Resonance Spectroscopy (MRS) You will then receive a standard dinner at \ 7pm and will be ask to switch off the light in your bedroom at \ 10pm The next morning investigators will wake you up at \ 4.45am to start an IV line and start a 8-hour procedure (Euglycemic Clamp) to measure how your body responds to insulin. You will be discharged from the inpatient unit between 2 and 3 pm after being fed a lunch. Visit 1 is Screening; Visit 2/7 is Wk0/17; Visit 3/8 is Wk1/18; Visit 4/9 is Wk3/20; Visit 5/10 is Wk5/22 and Visit 6/11 is Wk8/25 ECG: Screening Vital Signs, Height, Weight, Waist & Hip Measurements: Screening, Visit 3, Visit 4, Visit 5 & Visit 6 Fasting Blood & Urine Sample: Screening and Visit 6 Medical History & Physical Exam + Questionnaire Barriers: Screening Pick up pills/receive instructions: Visit 2, Visit 3, Visit 4, & Visit 5 Health Status/Medication Compliance Visit 3, Visit 4 & Visit 5 Admittance to Inpatient Unit: Visit 6 Body Composition (DXA): Visit 6 Body Composition (MRI): Visit 6 Liver/Muscle Fat (MRS): Visit 6 Euglycemic Clamp with biopsies: Visit 6 Eight weeks later (during which you will not take any pill), you will start the same sequence of visits (VISITS 7-11) as shown above for Visits 2-6 but this time with the other pill. DESCRIPTION OF PROCEDURES Euglycemic IV clamp (8 hours): This procedure measures how the body responds to insulin. Insulin is normally produced by your body during meals and helps your body use sugar. There will be 2 IV lines, one in your arm and one in your hand on the opposite side. Approximately 30 minutes after the IV lines are inserted; investigators will perform a fat biopsy to sample fat cells beneath the skin of your stomach area. Then, a muscle biopsy will be obtained to sample muscle cells beneath the skin of your thigh. Small amounts of glucose and insulin will be infused into your arm. Your blood sugar level will be checked every 5-10 minutes from the IV in your hand to determine how much glucose you should have to keep your blood sugar at a normal level. Your hand will be placed inside a warming box to increase skin temperature to about 105 degrees Fahrenheit. The temperature will be warm, but not uncomfortable. During your IV procedure, a small amount of your own blood (less than 1 teaspoon) will immediately be returned into your vein through the IV after each specimen is collected Three times during the 8-hour procedure, investigators will place a clear plastic hood, through which fresh air flows, over your head to measure how many calories your body burns. This measure will last 40 minutes each time. Your urine will be collected throughout the test in a urine jug (at the end of the test or in 2 collections if necessary). Fat biopsy (about 30 minutes): This procedure is used to sample fat cells from underneath the abdominal skin after cleansing the skin with iodine and using a local anesthetic. After cleansing the area, the doctor or Nurse Practitioner will make a small incision in the skin and introduce a needle under the skin to remove fat cells. About 1 gram (less than half a teaspoon size) of fat will be removed. After the biopsy is completed, the skin will be held closed with a sterile adhesive bandage; an antibiotic ointment will be applied. Risks: Fat Biopsy: Mild to severe pain, soreness, and bruising, and a small scar are common risks. There is a small risk of a hematoma (collection of blood in the tissue) or infection at the biopsy site. Sterile technique will be used to minimize these risks and the biopsy site will be monitored closely. Muscle Biopsy (about 30 minutes): This procedure is used to sample muscle cells from underneath the skin of the leg. After cleaning the skin with iodine and using a local anesthetic, the doctor or nurse practitioner will make a small incision in the skin and introduce a needle under the skin to remove muscle cells. About 200-750 milligrams (less than a teaspoon size) of muscle will be removed. After the biopsy is completed, the skin will be held closed with a sterile adhesive bandage and an antibiotic ointment will be applied. Risks: Muscle Biopsy: Mild to severe pain, soreness, bruising, and a small scar are common risks. A hematoma (collection of blood in the tissue) may occur. There is a slight risk that a superficial nerve may be cut; the nerve may heal, or it may result in a permanent loss of sensation in the skin at the biopsy site. DXA - Whole Body Scan (\ 4 minutes): This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes less than four minutes. This scan is for research purposes only and not for diagnostic treatment. MRI Abdomen (30 minutes): This scan measures the amount of fat in your abdomen. You will change into a hospital gown and remove all objects containing metal from your body. You will lie on your back on the scanner table with your arms above your head. A large coil will be placed around your upper abdomen. You will then be moved into the magnet and will be instructed to hold your breath 4-5 times (once for six seconds, once for 13 seconds, and 2-3 times for about 18 seconds after the upper abdominal scans are completed, you will be moved up on the table, and the coil will be placed over your lower abdomen. The same scans will be acquired over this area with the same 4-5 breath holds. The total scan time for this procedure is approximately 30 minutes. During the scan, you will hear loud tapping noises. You will be given headphones for protection from the scanner noise and can listen to music during the scan if desired. You will also be given a call button should you need the MRI Technician during the exam. This scan is for research purposes only and not for diagnostic treatment. MRS IHL (Intrahepatic lipid) (20-30 minutes): This scan measures the amount of fat in your liver. You will change into a hospital gown and remove all objects containing metal from your body. You will be placed on the scanner table head first and on your stomach. The table will move you into the magnet where data will be obtained. The scan will last for approximately 20-30 minutes. During the scan, you will hear loud tapping noises. You will be given head phones for protection from the scanner noise and can listen to music during the scan if desired. You will also be given a call button should you need the MRI tech during the exam. This scan is for research purposes only and not for diagnostic treatment. MRS IMCL (Intramyocellular lipid) (60 minutes): This scan measures the amount of fat in your muscle fibers. You will change into a hospital gown and remove all objects containing metal from your body. You will lie on your back on the scanner table with the right leg in a special coil. The top part of the coil will then be placed over your calf. Cushions will be inserted around the calf to help keep the leg as still as possible. The table will then move you into the scanner where a series of several scans will be obtained. The entire procedure will last approximately 60 minutes. During the scan, you will hear loud tapping noises. You will be given head phones for protection from the scanner noise and can listen to music during the scan if desired. You will also be given a call button should you need the MRI tech during the exam. This scan is for research purposes only and not for diagnostic treatment.

Interventions

DRUGTSEC (Tissue-selective estrogen complexes)

Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)

OTHERPlacebo

non active

Sponsors

Pennington Biomedical Research Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
50 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Post-menopausal women (\<5y post last period) * Age between 50-60y * Symptomatic (hot flashes, vaginal dryness) or asymptomatic * BMI 30-40 kg/m2 * Normal mammogram past 12 months * Physician clearance (Ob/Gyn or PBRC)

Exclusion criteria

* Amenorrhea other causes (excess androgen) * Diabetes mellitus * Medications: diabetes, antidepressant uncontrolled depression (2 months stability on SSRIs are fine), antipsychotics, oral steroids, weight loss drugs * Tricyclic antidepressants (TCAs) * ≤ 3 month washout of birth control pill, estrogen, and/or progestin * Hysterectomy (total or partial) * Contraindications to estrogen treatment * Unable or unwilling to do an MRS

Design outcomes

Primary

MeasureTime frame
Effect of CE/BZA (TSEC) on Body Composition8 weeks
Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy8 weeks
Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy)8 weeks
Effect of CE/BZA (TSEC) on Body Mass Index8 weeks
Effect of CE/BZA (TSEC) on Percent Body Fat8 weeks
Effect of CE/BZA (TSEC) on Fat Cell Ratio (Small/Large)8 weeks
Effect of CE/BZA (TSEC) on Mean Fat Cell Size8 weeks

Secondary

MeasureTime frameDescription
Effect of CE/BZA (TSEC) on Fasting Labs8 weeks
Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Insulin8 weeksLow-Dose Insulin \[20 mIU/min/m2 \] High-Dose Insulin \[120 mIU/min/m2 \]
Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp)8 weeksLow-Dose Insulin \[20 mIU/min/m2 \], High-Dose Insulin \[120 mIU/min/m2 \]
Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFA8 weeksLow-Dose Insulin \[20 mIU/min/m2 \] High-Dose Insulin \[120 mIU/min/m2 \]
Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)8 weeks
Effect of CE/BZA (TSEC) on Fasting Insulin8 weeks
Effect of CE/BZA (TSEC) on Fasting Free Fatty Acids8 weeks
Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Glucose8 weeksLow-Dose Insulin \[ 20 mIU/min/m2 \]

Countries

United States

Participant flow

Recruitment details

269 applied to participate. 82 completed a web base screening. 18 screened in the clinic. 10 were ineligible and 8 enrolled and were randomized and completed the study.

Pre-assignment details

the 10 ineligible were 5 BMI out of range. 2 \> 5 year post menopause. 1 because of medication. 1 for medical condition and 1 failed to return to clinic.

Participants by arm

ArmCount
Enrolled Female Participants
This study involves a screening process to see if you are eligible to participate followed by two 8-week treatment periods separated by an 8-week washout period. The two 8-week treatments will be with: 8 weeks of treatment with TSEC (Duavee™, combination of CE and BZA) 8 weeks of treatment with a dummy pill (Placebo) The order of these 2 8-week treatment periods will be decided by chance (coin flip).
8
Total8

Baseline characteristics

CharacteristicEnrolled Female Participants
Age, Customized
Age 50-60 years
8 years
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
6 Participants
Region of Enrollment
United States
8 Participants
Sex: Female, Male
Female
8 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 80 / 8
other
Total, other adverse events
7 / 85 / 8
serious
Total, serious adverse events
0 / 80 / 8

Outcome results

Primary

Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy)

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy)Small Fat Cells66.4 PercentStandard Deviation 8.7
PlaceboEffect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy)Large Fat Cells33.6 PercentStandard Deviation 8.7
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy)Small Fat Cells66.0 PercentStandard Deviation 5.5
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Abdominal Fat Cell Size (by Biopsy)Large Fat Cells34.0 PercentStandard Deviation 5.5
Primary

Effect of CE/BZA (TSEC) on Body Composition

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Body CompositionWeight91.3 KilogramsStandard Deviation 6.8
PlaceboEffect of CE/BZA (TSEC) on Body CompositionFat Mass45.5 KilogramsStandard Deviation 4.6
PlaceboEffect of CE/BZA (TSEC) on Body CompositionFat-free Mass46.0 KilogramsStandard Deviation 3.5
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Body CompositionWeight90.6 KilogramsStandard Deviation 7.2
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Body CompositionFat Mass45.7 KilogramsStandard Deviation 4
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Body CompositionFat-free Mass45.5 KilogramsStandard Deviation 4
Primary

Effect of CE/BZA (TSEC) on Body Mass Index

Time frame: 8 weeks

ArmMeasureValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Body Mass Index36.6 kilograms per meter squaredStandard Deviation 2.7
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Body Mass Index36.4 kilograms per meter squaredStandard Deviation 2.9
Primary

Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance Spectroscopy

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance SpectroscopyTibialis anterior intramyocellular lipid (IMCL)0.33 PercentStandard Deviation 0.23
PlaceboEffect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance SpectroscopyTibialis anterior extramyocellular lipid (EMCL)1.87 PercentStandard Deviation 1.6
PlaceboEffect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance SpectroscopyIntrahepatic Lipid (IHL)9.00 PercentStandard Deviation 13.9
PlaceboEffect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance SpectroscopySoleus intramyocellular lipid (IMCL)0.29 PercentStandard Deviation 0.27
PlaceboEffect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance SpectroscopySoleus extramyocellular lipid (EMCL)0.32 PercentStandard Deviation 0.28
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance SpectroscopySoleus extramyocellular lipid (EMCL)0.43 PercentStandard Deviation 0.45
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance SpectroscopySoleus intramyocellular lipid (IMCL)0.36 PercentStandard Deviation 0.47
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance SpectroscopyTibialis anterior extramyocellular lipid (EMCL)4.13 PercentStandard Deviation 6.06
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance SpectroscopyTibialis anterior intramyocellular lipid (IMCL)0.69 PercentStandard Deviation 0.5
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Ectopic Fat - 1H-MRS, Proton Magnetic Resonance SpectroscopyIntrahepatic Lipid (IHL)8.06 PercentStandard Deviation 9.14
Primary

Effect of CE/BZA (TSEC) on Fat Cell Ratio (Small/Large)

Time frame: 8 weeks

ArmMeasureValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Fat Cell Ratio (Small/Large)2.19 ratioStandard Deviation 1
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Fat Cell Ratio (Small/Large)2.00 ratioStandard Deviation 0.45
Primary

Effect of CE/BZA (TSEC) on Mean Fat Cell Size

Time frame: 8 weeks

ArmMeasureValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Mean Fat Cell Size1.35 um^3 (x10^6)Standard Deviation 0.4
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Mean Fat Cell Size1.6 um^3 (x10^6)Standard Deviation 0.4
Primary

Effect of CE/BZA (TSEC) on Percent Body Fat

Time frame: 8 weeks

ArmMeasureValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Percent Body Fat50.9 percentage of total body weightStandard Deviation 2.5
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Percent Body Fat51.4 percentage of total body weightStandard Deviation 1.9
Secondary

Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp)

Low-Dose Insulin \[20 mIU/min/m2 \], High-Dose Insulin \[120 mIU/min/m2 \]

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp)Basal SGO2.83 mg/min [FFM+17.7]Standard Deviation 0.41
PlaceboEffect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp)GDR at Low-Dose Insulin2.48 mg/min [FFM+17.7]Standard Deviation 0.91
PlaceboEffect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp)GDR at High-Dose Insulin11.99 mg/min [FFM+17.7]Standard Deviation 4.49
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp)Basal SGO2.68 mg/min [FFM+17.7]Standard Deviation 0.32
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp)GDR at Low-Dose Insulin2.55 mg/min [FFM+17.7]Standard Deviation 1.04
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp)GDR at High-Dose Insulin11.68 mg/min [FFM+17.7]Standard Deviation 4.23
Secondary

Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Glucose

Low-Dose Insulin \[ 20 mIU/min/m2 \]

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on GlucoseLow-Dose Glucose90 mg/dLStandard Deviation 1
PlaceboEffect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on GlucoseHigh-Dose Glucose97 mg/dLStandard Deviation 3
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on GlucoseLow-Dose Glucose88 mg/dLStandard Deviation 1
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on GlucoseHigh-Dose Glucose95 mg/dLStandard Deviation 3
Secondary

Effect of CE/BZA (TSEC) on Fasting Free Fatty Acids

Time frame: 8 weeks

ArmMeasureValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Fasting Free Fatty Acids0.72 mmol/LStandard Deviation 0.06
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Fasting Free Fatty Acids0.78 mmol/LStandard Deviation 0.06
Secondary

Effect of CE/BZA (TSEC) on Fasting Insulin

Time frame: 8 weeks

ArmMeasureValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Fasting Insulin16.6 uU/mLStandard Deviation 2.8
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Fasting Insulin15.7 uU/mLStandard Deviation 2.8
Secondary

Effect of CE/BZA (TSEC) on Fasting Labs

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Fasting LabsTotal cholesterol179 Milligrams/deciliterStandard Deviation 34
PlaceboEffect of CE/BZA (TSEC) on Fasting LabsHDL-cholesterol51 Milligrams/deciliterStandard Deviation 11
PlaceboEffect of CE/BZA (TSEC) on Fasting LabsTriglycerides138 Milligrams/deciliterStandard Deviation 75
PlaceboEffect of CE/BZA (TSEC) on Fasting LabsLDL-cholesterol100 Milligrams/deciliterStandard Deviation 24
PlaceboEffect of CE/BZA (TSEC) on Fasting LabsGlucose105 Milligrams/deciliterStandard Deviation 4
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Fasting LabsLDL-cholesterol99 Milligrams/deciliterStandard Deviation 20
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Fasting LabsGlucose102 Milligrams/deciliterStandard Deviation 4
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Fasting LabsTotal cholesterol187 Milligrams/deciliterStandard Deviation 32
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Fasting LabsTriglycerides156 Milligrams/deciliterStandard Deviation 73
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Fasting LabsHDL-cholesterol57 Milligrams/deciliterStandard Deviation 14
Secondary

Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFA

Low-Dose Insulin \[20 mIU/min/m2 \] High-Dose Insulin \[120 mIU/min/m2 \]

Time frame: 8 weeks

Population: No data reported for FFA for High-Dose Insulin

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFAFree Fatty Acids (FFA) at Low-Dose Insulin0.13 mmol/LStandard Deviation 0.05
PlaceboEffect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFAFree Fatty Acids (FFA) at High-Dose Insulin0 mmol/LStandard Deviation 0
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFAFree Fatty Acids (FFA) at Low-Dose Insulin0.13 mmol/LStandard Deviation 0.05
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on FFAFree Fatty Acids (FFA) at High-Dose Insulin0 mmol/LStandard Deviation 0
Secondary

Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on Insulin

Low-Dose Insulin \[20 mIU/min/m2 \] High-Dose Insulin \[120 mIU/min/m2 \]

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on InsulinInsulin at Low-Dose Insulin37.8 uU/mLStandard Deviation 2.4
PlaceboEffect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on InsulinInsulin at High-Dose Insulin250.8 uU/mLStandard Deviation 19.3
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on InsulinInsulin at High-Dose Insulin259.8 uU/mLStandard Deviation 19.3
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Insulin Sensitivity (by Hyperinsulinemic-Euglycemic Clamp) on InsulinInsulin at Low-Dose Insulin34.8 uU/mLStandard Deviation 2.4
Secondary

Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)

Low-Dose Insulin \[20 mIU/min/m2 \], High-Dose Insulin \[120 mIU/min/m2 \]

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Respiratory Quotient (RQ) at Basal0.81 unitlessStandard Deviation 0.03
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Respiratory Quotient (RQ) at Low-Dose0.85 unitlessStandard Deviation 0.04
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Respiratory Quotient (RQ) at Hight-Dose0.92 unitlessStandard Deviation 0.05
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Respiratory Quotient (RQ) at Hight-Dose0.91 unitlessStandard Deviation 0.06
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Respiratory Quotient (RQ) at Basal0.80 unitlessStandard Deviation 0.03
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Respiratory Quotient (RQ) at Low-Dose0.83 unitlessStandard Deviation 0.03
Secondary

Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)

Low-Dose Insulin \[20 mIU/min/m2 \], High-Dose Insulin \[120 mIU/min/m2 \]

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Oxidation at Basal1.2 mg/min/[FFM+17.7]Standard Deviation 0.1
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Storage at Basal1.6 mg/min/[FFM+17.7]Standard Deviation 0.3
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Oxidation at Low-Dose1.6 mg/min/[FFM+17.7]Standard Deviation 0.1
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Storage at Low-dose0.9 mg/min/[FFM+17.7]Standard Deviation 0.3
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Oxidation at High-Dose2.7 mg/min/[FFM+17.7]Standard Deviation 0.3
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Storage at High-Dose9.3 mg/min/[FFM+17.7]Standard Deviation 1.4
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Oxidation at High-Dose2.7 mg/min/[FFM+17.7]Standard Deviation 0.3
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Oxidation at Basal1.0 mg/min/[FFM+17.7]Standard Deviation 0.1
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Storage at Low-dose1.2 mg/min/[FFM+17.7]Standard Deviation 0.3
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Storage at Basal1.6 mg/min/[FFM+17.7]Standard Deviation 0.3
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Storage at High-Dose9.0 mg/min/[FFM+17.7]Standard Deviation 1.4
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Carbohydrate Oxidation at Low-Dose1.3 mg/min/[FFM+17.7]Standard Deviation 0.1
Secondary

Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)

Time frame: 8 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Resting Metabolic Rate (RMR) on Basal1410 kcal/dayStandard Deviation 126
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Resting Metabolic Rate (RMR) on Low-Dose Insulin1379 kcal/dayStandard Deviation 94
PlaceboEffect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Resting Metabolic Rate (RMR) on High-Dose Insulin1516 kcal/dayStandard Deviation 113
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Resting Metabolic Rate (RMR) on Low-Dose Insulin1378 kcal/dayStandard Deviation 137
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Resting Metabolic Rate (RMR) on Basal1471 kcal/dayStandard Deviation 161
TSEC (Duavee™, Combination of CE and BZA)Effect of CE/BZA (TSEC) on Resting Metabolic Rate & Substrate Oxidation (by Indirect Calorimetry)Resting Metabolic Rate (RMR) on High-Dose Insulin1576 kcal/dayStandard Deviation 83

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026